Alexander John Lander
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alexander John Lander has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Louis Yu Pan Luk
Cardiff University
4 shared publications - Daniel Ricklin
Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
3 shared publications - Yi Jin
Manchester Institute of Biotechnology, The University of Manchester, M1 7DN, UK
3 shared publications - Ekaterina S. Umnyakova
Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
2 shared publications Jannes Felsch
Department of Pharmaceutical Sciences
2 shared publications- John D. Lambris
University of Pennsylvania
2 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 11592-11609
New Analogs of the Compstatin Family of Clinical Complement Inhibitors with Low Picomolar Target Affinity
Compstatin-class macrocyclic peptides have emerged as therapeutic complement modulators, with a PEGylated compstatin derivative being approved and sequence-optimized analogs with enhanced PK/PD properties showing clinical promise. By extending structure-activity relationship studies of compstatin, we identified a modification (V3I) that enhances the target affinity up to 30-fold. Analog Cp01-V3I represents the most potent proteinogenic compstatin (KD = 20 nM), opening paths toward recombinant applications. Introducing the V3I modification into late-generation compstatin analogs yielded a low-picomolar-affinity derivative (KD = 0.08 nM), termed Cp60, featuring potent complement inhibition in vitro. Cryogenic electron microscopy of the C3bB-Cp60 complex at 2.88 Å resolution confirmed the structural basis for enhanced target affinity and provided mechanistic insights. Lastly, we demonstrate that Cp60s ultralong target residence time enables diagnostic applications for detecting complement opsonins on biosurfaces. Collectively, this work highlights the importance of rigorous optimization of de novo peptide inhibitors to improve PK/PD properties and enable novel applications.
- 1 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 11592-11609
Open AccessNew Analogs of the Compstatin Family of Clinical Complement Inhibitors with Low Picomolar Target Affinity
Compstatin-class macrocyclic peptides have emerged as therapeutic complement modulators, with a PEGylated compstatin derivative being approved and sequence-optimized analogs with enhanced PK/PD properties showing clinical promise. By extending structure-activity relationship studies of compstatin, we identified a modification (V3I) that enhances the target affinity up to 30-fold. Analog Cp01-V3I represents the most potent proteinogenic compstatin (KD = 20 nM), opening paths toward recombinant applications. Introducing the V3I modification into late-generation compstatin analogs yielded a low-picomolar-affinity derivative (KD = 0.08 nM), termed Cp60, featuring potent complement inhibition in vitro. Cryogenic electron microscopy of the C3bB-Cp60 complex at 2.88 Å resolution confirmed the structural basis for enhanced target affinity and provided mechanistic insights. Lastly, we demonstrate that Cp60s ultralong target residence time enables diagnostic applications for detecting complement opsonins on biosurfaces. Collectively, this work highlights the importance of rigorous optimization of de novo peptide inhibitors to improve PK/PD properties and enable novel applications.
- Open Access
- 4 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
New analogs of the compstatin family of clinical complement inhibitors with low picomolar target affinity
Macrocyclic peptides of the compstatin family have emerged as therapeutic complement system modulators. Alongside an approved PEGylated derivative, sequence-optimized compstatin analogs with enhanced PK/PD properties have shown clinical promise. By extending the structure-activity relationship of compstatin, we characterized a highly beneficial V3I modification that enhances compstatin’s target affinity up to 30-fold and show that the additional gamma-methyl group addresses a specific target pocket. Novel analog Cp01-V3I represents the most potent analog comprised entirely of canonical amino acids (KD = 20 nM), opening a path toward recombinant applications. Meanwhile, the V3I modification can be transferred to late-generation analogs to obtain a low-picomolar-affinity derivative (KD = 0.08 nM), termed Cp60, with potent complement inhibition in vitro. Lastly, we demonstrate that Cp60’s ultra-long target residence enables new applications as a diagnostic tool for the detection of complement opsonins on biosurfaces. Collectively, this work highlights the importance of vigorous optimization of de novo peptide inhibitors to improve PK/PD properties and enable novel applications.
- 4 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessNew analogs of the compstatin family of clinical complement inhibitors with low picomolar target affinity
Macrocyclic peptides of the compstatin family have emerged as therapeutic complement system modulators. Alongside an approved PEGylated derivative, sequence-optimized compstatin analogs with enhanced PK/PD properties have shown clinical promise. By extending the structure-activity relationship of compstatin, we characterized a highly beneficial V3I modification that enhances compstatin’s target affinity up to 30-fold and show that the additional gamma-methyl group addresses a specific target pocket. Novel analog Cp01-V3I represents the most potent analog comprised entirely of canonical amino acids (KD = 20 nM), opening a path toward recombinant applications. Meanwhile, the V3I modification can be transferred to late-generation analogs to obtain a low-picomolar-affinity derivative (KD = 0.08 nM), termed Cp60, with potent complement inhibition in vitro. Lastly, we demonstrate that Cp60’s ultra-long target residence enables new applications as a diagnostic tool for the detection of complement opsonins on biosurfaces. Collectively, this work highlights the importance of vigorous optimization of de novo peptide inhibitors to improve PK/PD properties and enable novel applications.
- Open Access
- 5 September 2025
- Published by Wiley in Advanced Materials Interfaces
- Vol. 12 (19)
Assay System Based on Metabolic Glycoengineering‐Enabled Click Chemistry for the Efficient Evaluation of Complement‐Regulatory Peptide Coatings on Endothelial Cells
Protective cell‐surface coatings with complement‐regulatory activity emerge as promising therapeutic strategies, particularly for preventing thromboinflammatory complications during transplantation. However, their development and in vitro evaluation require specialized assay systems. This study establishes an efficient platform to coat endothelial cells with peptides that recruit the physiological complement regulator factor H (FH) and test their activity. Azide‐groups are introduced into cell‐surface glycans of human and porcine endothelial cells via metabolic glycoengineering to enable covalent attachment of alkyne‐labeled FH‐binding peptides via click chemistry. By optimizing the type and concentration of azido‐sugars, effective incorporation of accessible click handles can be achieved with minimal impact on cell viability. This approach results in uniform, controllable peptide coatings that efficiently recruit FH from purified sources and human serum to endothelial cell surfaces and enhance their resistance to complement‐mediated opsonization. This model not only served as validation for the efficacy of FH‐recruiting peptides but also provides a versatile platform to evaluate and optimize various parameters that define coating efficacy and gain insight into mechanisms of complement activation. As such, it may facilitate the screening of modulators and the development of protective coatings for future applications in biomedical or preclinical research.
- 5 September 2025
- Published by Wiley in Advanced Materials Interfaces
- Vol. 12 (19)
Open AccessAssay System Based on Metabolic Glycoengineering‐Enabled Click Chemistry for the Efficient Evaluation of Complement‐Regulatory Peptide Coatings on Endothelial Cells
Protective cell‐surface coatings with complement‐regulatory activity emerge as promising therapeutic strategies, particularly for preventing thromboinflammatory complications during transplantation. However, their development and in vitro evaluation require specialized assay systems. This study establishes an efficient platform to coat endothelial cells with peptides that recruit the physiological complement regulator factor H (FH) and test their activity. Azide‐groups are introduced into cell‐surface glycans of human and porcine endothelial cells via metabolic glycoengineering to enable covalent attachment of alkyne‐labeled FH‐binding peptides via click chemistry. By optimizing the type and concentration of azido‐sugars, effective incorporation of accessible click handles can be achieved with minimal impact on cell viability. This approach results in uniform, controllable peptide coatings that efficiently recruit FH from purified sources and human serum to endothelial cell surfaces and enhance their resistance to complement‐mediated opsonization. This model not only served as validation for the efficacy of FH‐recruiting peptides but also provides a versatile platform to evaluate and optimize various parameters that define coating efficacy and gain insight into mechanisms of complement activation. As such, it may facilitate the screening of modulators and the development of protective coatings for future applications in biomedical or preclinical research.
- Open Access
- 11 December 2023
- Published by American Chemical Society (ACS) in ACS Bio & Med Chem Au
- Vol. 4 (1) , 68-76
Deciphering the Synthetic and Refolding Strategy of a Cysteine-Rich Domain in the Tumor Necrosis Factor Receptor (TNF-R) for Racemic Crystallography Analysis and d-Peptide Ligand Discovery
Many cell-surface receptors are promising targets for chemical synthesis because of their critical roles in disease development. This synthetic approach enables investigations by racemic protein crystallography and ligand discovery by mirror-image methodologies. However, due to their complex nature, the chemical synthesis of a receptor can be a significant challenge. Here, we describe the chemical synthesis and folding of a central, cysteine-rich domain of the cell-surface receptor tumor necrosis factor 1 which is integral to binding of the cytokine TNF-alpha, namely, TNFR-1 CRD2. Racemic protein crystallography at 1.4 & Aring; confirmed that the native binding conformation was preserved, and TNFR-1 CRD2 maintained its capacity to bind to TNF-alpha (K-D approximate to 7 nM). Encouraged by this discovery, we carried out mirror-image phage display using the enantiomeric receptor mimic and identified a d-peptide ligand for TNFR-1 CRD2 (K-D = 1 mu M). This work demonstrated that cysteine-rich domains, including the central domains, can be chemically synthesized and used as mimics for investigations.
- 11 December 2023
- Published by American Chemical Society (ACS) in ACS Bio & Med Chem Au
- Vol. 4 (1) , 68-76
Open AccessDeciphering the Synthetic and Refolding Strategy of a Cysteine-Rich Domain in the Tumor Necrosis Factor Receptor (TNF-R) for Racemic Crystallography Analysis and d-Peptide Ligand Discovery
Many cell-surface receptors are promising targets for chemical synthesis because of their critical roles in disease development. This synthetic approach enables investigations by racemic protein crystallography and ligand discovery by mirror-image methodologies. However, due to their complex nature, the chemical synthesis of a receptor can be a significant challenge. Here, we describe the chemical synthesis and folding of a central, cysteine-rich domain of the cell-surface receptor tumor necrosis factor 1 which is integral to binding of the cytokine TNF-alpha, namely, TNFR-1 CRD2. Racemic protein crystallography at 1.4 & Aring; confirmed that the native binding conformation was preserved, and TNFR-1 CRD2 maintained its capacity to bind to TNF-alpha (K-D approximate to 7 nM). Encouraged by this discovery, we carried out mirror-image phage display using the enantiomeric receptor mimic and identified a d-peptide ligand for TNFR-1 CRD2 (K-D = 1 mu M). This work demonstrated that cysteine-rich domains, including the central domains, can be chemically synthesized and used as mimics for investigations.
- Open Access
- 18 July 2023
- Published by Springer Nature in Communications Chemistry
- Vol. 6 (1) , 1-7
Roles of inter- and intramolecular tryptophan interactions in membrane-active proteins revealed by racemic protein crystallography
Tryptophan is frequently found on the surface of membrane-associated proteins that interact with the lipid membrane. However, because of their multifaceted interactions, it is difficult to pinpoint the structure-activity relationship of each tryptophan residue. Here, we describe the use of racemic protein crystallography to probe dedicated tryptophan interactions of a model tryptophan-rich bacteriocin aureocin A53 (AucA) by inclusion and/or exclusion of potential ligands. In the presence of tetrahedral anions that are isosteric to the head group of phospholipids, distinct tryptophan H-bond networks were revealed. H-bond donation by W40 was critical for antibacterial activity, as its substitution by 1-methyltryptophan resulted in substantial loss of activity against bacterial clinical isolates. Meanwhile, exclusion of tetrahedral ions revealed that W3 partakes in formation of a dimeric interface, thus suggesting that AucA is dimeric in solution and dissociated to interact with the phosphate head group in the presence of the lipid membrane. Based on these findings, we could predict the tryptophan residue responsible for activity as well as the oligomeric state of a distant homologue lacticin Q (48%).
- 18 July 2023
- Published by Springer Nature in Communications Chemistry
- Vol. 6 (1) , 1-7
Open AccessRoles of inter- and intramolecular tryptophan interactions in membrane-active proteins revealed by racemic protein crystallography
Tryptophan is frequently found on the surface of membrane-associated proteins that interact with the lipid membrane. However, because of their multifaceted interactions, it is difficult to pinpoint the structure-activity relationship of each tryptophan residue. Here, we describe the use of racemic protein crystallography to probe dedicated tryptophan interactions of a model tryptophan-rich bacteriocin aureocin A53 (AucA) by inclusion and/or exclusion of potential ligands. In the presence of tetrahedral anions that are isosteric to the head group of phospholipids, distinct tryptophan H-bond networks were revealed. H-bond donation by W40 was critical for antibacterial activity, as its substitution by 1-methyltryptophan resulted in substantial loss of activity against bacterial clinical isolates. Meanwhile, exclusion of tetrahedral ions revealed that W3 partakes in formation of a dimeric interface, thus suggesting that AucA is dimeric in solution and dissociated to interact with the phosphate head group in the presence of the lipid membrane. Based on these findings, we could predict the tryptophan residue responsible for activity as well as the oligomeric state of a distant homologue lacticin Q (48%).
- Open Access
- 16 November 2022
- Published by Wiley in ChemBioChem
- Vol. 24 (4) , e202200537
D‐Peptide and D‐Protein Technology: Recent Advances, Challenges, and Opportunities**
Total chemical protein synthesis provides access to entire D‐protein enantiomers enabling unique applications in molecular biology, structural biology, and bioactive compound discovery. Key enzymes involved in the central dogma of molecular biology have been prepared in their D‐enantiomeric forms facilitating the development of mirror‐image life. Crystallization of a racemic mixture of L‐ and D‐protein enantiomers provides access to high‐resolution X‐ray structures of polypeptides. Additionally, D‐enantiomers of protein drug targets can be used in mirror‐image phage display allowing discovery of non‐proteolytic D‐peptide ligands as lead candidates. This review discusses the unique applications of D‐proteins including the synthetic challenges and opportunities.
- 16 November 2022
- Published by Wiley in ChemBioChem
- Vol. 24 (4) , e202200537
Open AccessD‐Peptide and D‐Protein Technology: Recent Advances, Challenges, and Opportunities**
Total chemical protein synthesis provides access to entire D‐protein enantiomers enabling unique applications in molecular biology, structural biology, and bioactive compound discovery. Key enzymes involved in the central dogma of molecular biology have been prepared in their D‐enantiomeric forms facilitating the development of mirror‐image life. Crystallization of a racemic mixture of L‐ and D‐protein enantiomers provides access to high‐resolution X‐ray structures of polypeptides. Additionally, D‐enantiomers of protein drug targets can be used in mirror‐image phage display allowing discovery of non‐proteolytic D‐peptide ligands as lead candidates. This review discusses the unique applications of D‐proteins including the synthetic challenges and opportunities.
- Open Access
- 12 May 2020
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 11 (23) , 5881-5888
Use of an asparaginyl endopeptidase for chemo-enzymatic peptide and protein labeling
Asparaginyl endopeptidases (AEP) are ideal for peptide and protein labeling. Its pairing with a simple chemical reaction significantly lowers the amount of label needed for effective bioconjugation.
- 12 May 2020
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 11 (23) , 5881-5888
Open AccessUse of an asparaginyl endopeptidase for chemo-enzymatic peptide and protein labeling
Asparaginyl endopeptidases (AEP) are ideal for peptide and protein labeling. Its pairing with a simple chemical reaction significantly lowers the amount of label needed for effective bioconjugation.